Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study. by Tateishi, M. et al.
Br. J. Cancer (1991), 63, 130-133 © Macmillan Press Ltd.,
Prognostic implication of transforming growth factor a. in
adenocarcinoma of the lung an immunohistochemical study
M. Tateishi, T. Ishida, T. Mitsudomi & K. Sugimachi
Department ofSurgery II, Faculty ofMedicine, Kyushu University, Fukuoka, Japan.
Summary We examined for transforming growth factora (TGFa) in adenocarcinomatous lesions of the lung
tissues excised from 138 patients, with use of the avidin-biotin-peroxidase complex (ABC) method. TGFa was
present in the cytoplasm of the adenocarcinoma. Our objective was to determine if TGFa could serve as a
prognostic parameter. We divided 138 patients into two groups according to the concentration of TGFa.
Ninety-two patients had a high concentration of TGFa, in over 75% of the tumour cells, while 46 had a low
concentration, that is in less than 75% of the cells. The 5-year survival rates of patients with high TGFa and
low TGFa were 39% and 64%, respectively (P <0.05). Our data suggest that evidence of a high immunoreac-
tivity of TGFa can serve as a prognostic parameter in adenocarcinoma of the lung.
Human transforming growth factora (TGFa), a mitogenic
polypeptide, is composed of 50 amino acids. There is a 42%
homology with human epidermal growth factor (EGF)
(Derynck et al., 1984; Marquardt et al., 1984; Lee et al.,
1985). TGFa binds to the EGF receptor (EGFR) and the
binding affinity is equal to that of EGF (Lynsley et al., 1985).
It is generally accepted that the actions of TGFa are
mediated through EGFR. After binding to EGFR, TGFx
activates the tyrosine kinase subunit and autophosphoryla-
tion of the receptor occurs (Reynolds et al., 1981).
TGF-like factor has been noted in conditioned media,
from a variety of human tumour cell lines as well as from cell
extracts (Salmon et al., 1984; Hamburger et al., 1985; Smith
et al., 1987; Coffey Jr et al., 1987; Betsholtz et al., 1987).
TGFa has also been extracted from newly excised human
malignant neoplasms (Nickell et al., 1983) and is also present
in urine (Sherwin et al., 1983) or effusions (Hanauske et al.,
1988) of cancer patients. These data showed the close rela-
tion between TGFa and growth of malignant cells.
The prognostic significance of TGFa in human lung
adenocarcinoma, as determined immunohistochemically, has
apparently not been reported. We examined the usefulness of
TGFox as a possible prognostic parameter in adenocarcinoma
of the lung.
Materials and methods
For this study, we used paraffin embedded tissues excised
from 138 patients with primary adenocarcinoma of the lung.
All the patients has been diagnosed and treated in The
Department of Surgery II, Faculty of Medicine, Kyushu
University between 1974 and 1986. Patients who died within
the first post-operative month or who underwent exploratory
thoracotomy were excluded from the present analysis. Stage
of the disease was classified according to the TNM
classifiction of UICC (UICC, 1987), including a review of the
surgical and pathological reports of the resected specimens.
There were 69 patients with stage I, 12 with stage II, 32 with
stage IIIA, 11 with stage IIIB and 14 with stage IV. Of these
patients, 83 were men and 55 were women. The ages varied
from 39 to 81 years (mean 63 years). Histological degree of
differentiation of the WHO classification was used (WHO,
1982); 75 were well differentiated, 44 moderately and 18
poorly differentiated. One was unclassified. For all patients,
the intraoperative decision was curative, lobectomy with
complete hilar and mediastinum lymph nodes dissection and
no evidence of a residual tumour. The patients' records were
reviewed and computerised in June 1989.
The resected specimens were fixed in 10% formalin and
paraffin sections were prepared. For their histological studies,
the sections were stained with hematoxylin and eosin (HE).
The process of immunohistochemical staining was as follows;
the deparaffinised sections were treated with 0.03% hydrogen
peroxidase in methanol for 30min at room temperature to
inhibit endogenous peroxidase. After washing in phosphate
buffered saline (PBS) and incubating with normal goat serum
(diluted 1:200, 30 min, PK-4005; Vector Laboratories Burlin-
game, CA, USA), each section was incubated at room
temperature overnight with goat anti-human TGFa (diluted
1:100, PA-125-G; BIOTOP, Washington, USA). After this
incubation, sections were washed well with PBS. For the
avidin-biotin-peroxidase complex (ABC) technique (Hsu et
al., 1981), the Vectastain ABC kit for goat immunoglobulin
(PK-4005; Vector Laboratories, Burlingame, CA) was used.
After these treatments, visualisation of the peroxidase was
achieved by the diaminobenzidine method. Each section was
then stained with methyl green and examined under a trans-
mission light microscope. Omission of the primary antibody
resulted in negative staining. When the sections were
incubated with human TGFa (5 ng, TR-123-U; BIOTOP,
Washington, USA) and then with anti-human TGFx, there
was a negative staining.
The extent of the immunoreactivity was grouped into
three, as follows: +, focal immunoreactivity staining of less
than 25% of the tumour cells; + +, moderate immunoreac-
tivity staining of 25-74% of the tumour cells; +++,
intense immunoreactivity staining of more than 75% of the
tumour cells.
The x2 test was used to analyse correlations among
immunoreactivities of TGFa and factors of sex, stage,
curability of operation and histologic type of differentiation.
The survival rate was calculated by the Kaplan-Meier
method (Kaplan et al., 1958). Comparisons among survival
rates were made by the log rank test (Peto et al., 1977).
Multivariate analysis was performed using Cox's propor-
tional hazards regression model (Cox, 1972). Computations
were carried out using the statistical package, BMDP (Dixon,
1985) 1L and 2L, on an IBM system 4381 computer. The
difference was considered to be significant when the P value
was less than 0.05.
Results
Immunoperoxidase reactivity for TGFa was evident in the
cytoplasm of the cancer cells (Figure la,b), however, there
was no staining in exudates produced by the cancer cells. In
the normal bronchial epithelium, TGFa was weak along the
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Figure 1 Immunostaining for TGFa in human lung adenocar-
cinoma, forming a papillary or tubular pattern. a, high, diffuse
immunoreactivity staining of tumour cells (x 130/inset; x 520),
b, low, focal immunoreactivity staining of tumour cells (x 130/
inset; x 520).
Table I The 5-year survival rates of patients with lung
adenocarcinoma separated according to the immunoreactivity of
TGFa
No. of 5-year survival
Variables TGFa patients rate (%)
T
2
3
4
N
0
2
M
0
Stage
I
II
IIIA
IIIB
IV
Differentiation
Well
Moderately
Poorly
Unknown
Total
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Low
Low
High
20
35
18
37
4
10
4
10
32
54
3
12
11
26
44
80
2
12
28
41
3
9
10
22
3
8
2
12
25
50
12
32
8
10
1
46
92
84
59
53
32
50
30
33
20
74
57
33
13
45
11
67
44
0
0
78
65
33
17
58
24
50
25
0
0
63
42
75
31
50
51
64
39
N.S.
N.S.
N.S.
N.S.
N.S.
N.S.
P <0.05
N.S.
N.S.
N.S.
N.S.
P <0.05
N.S.
N.S.
N.S.
N.S.
N.S.
P <0.05
N.S.: not significant.
100
brush borders of the epithelium. In the bronchial glands,
TGFa was seen in some cases.
Of 138 patients examined, 92 (67%) was classified as
+ + +, 19 (14%) as + + and 27 (19%) as +. Data assessed
included factors of T (tumour) status, N (node), M (meta-
stasis), stage, pathologic grade of differentiation and
curability of operation according to the extent of TGFa.
There was no statistically significant difference among the
extents of TGFa.
The 5-year survival rates of patients with +, + + and
+ + + were 60%, 70% and 39%, respectively. The extent of
both + and + + was designed low TGFa, and that of
+ + + was high TGFa. The 5-year survival rates of patients
separated by immunoreactivity of TGFO are shown in Table
I. In case of N2 and stage IIIA, there were statistically
significant differences in the survival rates of patients with
high TGFax and low TGFa (P <0.05). As shown in Figure 2,
the 5-year survival rates of overall patients with high TGFax
and low TGFa were 39% and 64%, respectively (P <0.05).
To compare the prognostic significance of variables, a
multivariate analysis were performed. Significant variables
for survival were recognised in the factors of TGFa, N, and
stage (P <0.05) (Table II).
> _
> 50
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Figure 2 Survival curves of patients with lung adenocarcinoma,
according to the extent of TGFax: *, 'high' and 0, 'low'. The
difference is significant between the two groups (P <0.05).
Discussion
TGFx plays a role in modulating cellular proliferation and
differentiation (Bennet et al., 1989). This growth factor is
secreted from transformed and from non-transformed cells.
Thus TGFa is involved in autocrine and/or paracrine
stimulation in epithelial proliferation and repair, without an
associated malignant transformation (Coffey Jr et al., 1987;
Madtes et al., 1988).
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Table II Multivariate analysis of various clinico-pathological
factors and TGFa in patients with lung adenocarcinoma
Variables No. (%) of patients P value
TGFa
Low 46 (33) 0.037 High 92 (67)0.3
Sex
Male 83 (60) N.S Female 55 (40)
T
1 55 (40)
2 55 (40) N.S.
3 14 (10)
4 14 (10)
N
0 86 (62)
1 15 (11) 0.027
2 37 (27)
M
0 124 (90) N.S 1 14 (10) *.S
Stage
I 69 (50)
II 12 (9)
IIIA 32 (23) 0.000
IIIB 11(8)
IV 14 (10)
Differentiation
Well 75 (54)
Moderately 44 (32) N.S Poorly 18 (14)
Unknown I
Curability
Curative 103 (75) NS
Non-curative 35 (25)
Total 138
N.S.: not significant.
Messenger RNA (mRNA) encoding both TGFa and
EGFR is present in human tumours (Macias et al., 1987;
Derynck et al., 1987). In a malignant tumour, the co-
expression of mRNA encoding both TGFa and EGFR is
higher than that in cases of inflammatory disease (Bennet et
al., 1989). Malignant cells originating from pancreatic cancer
overexpressing EGFR, synthesised in vitro a considerable
amount of mRNA encoding TGFa (Smith et al., 1987). The
presence of both TGFa and EGFR in the same tissue sug-
gests the involvement of autocrine mechanisms, that is, its
own growth factor is secreted.
TGF-like factor was detected in lung cancer cell lines
(Hamburger et al., 1985; Betsholtz et al., 1987). We obtained
immunohistochemical evidence of TGRa in tissues from
human lung adenocarcinoma. Intense staining for TGFa in
more than 75% of the tumour cells was detected in 67% of
the lesions and the amount of TGFa correlated well with the
prognosis of the advanced stage, especially in those with N2
stage of the disease.
EGF which is structurally related to TGFa proved to be
prognostic parameter in cases ofgastric cancer (Tahara et al.,
1986). The immunoreactivity of EGF in early gastric car-
cinoma was not evident (Japanese Research Society for
Gastric Cancer, 1981), while EGF was detected 21% of
advanced gastric carcinomas and 33% of the scirrhous car-
cinomas. Thus, the co-expression of both TGFa and EGFR
in lung cancer has to be examined using immunohis-
tochemical assays. Comparative studies should clarify the
potential of cancer cells to produce and respond to their own
growth factor, such as tumour invasiveness, lymphatic
permeation or vascular metastasis.
The prognosis of patients with advanced lung cancer is
poor; 15% of the patients in stage IIIA survive for 5 years
(Mountain, 1986) and 14% with an adenocarcinoma and N2
disease survive for 5 years (Mountain, 1985). All our patients
with an advanced lung cancer and high concentrations of
TGFa had a poor prognosis.
We thank K. Akazawa for the data analysis and M. Ohara for
helpful comments.
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